Emma Hughes1, Erika Wallender2, Richard Kajubi3, Prasanna Jagannathan4, Teddy Ochieng3, Abel Kakuru3, Moses R Kamya3,5, Tamara D Clark6, Philip J Rosenthal6, Grant Dorsey6, Francesca Aweeka2, Radojka M Savic1. 1. Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA. 2. Department of Clinical Pharmacy, University of California San Francisco, San Francisco, California, USA. 3. Infectious Disease Research Collaboration, Kampala, Uganda. 4. Department of Medicine, Stanford University, Stanford, California, USA. 5. Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda. 6. Department of Medicine, University of California San Francisco, San Francisco, California, USA.
Abstract
BACKGROUND: Intermittent preventive treatment with monthly dihydroartemisinin-piperaquine (DHA-PQ) is highly effective at preventing both malaria during pregnancy and placental malaria. Piperaquine prolongs the corrected QT interval (QTc), and it is possible that repeated monthly dosing could lead to progressive QTc prolongation. Intensive characterization of the relationship between piperaquine concentration and QTc interval throughout pregnancy can inform effective, safe prevention guidelines. METHODS: Data were collected from a randomized controlled trial, where pregnant Ugandan women received malaria chemoprevention with monthly DHA-PQ (120/960 mg DHA/PQ; n = 373) or sulfadoxine-pyrimethamine (SP; 1500/75 mg; n = 375) during the second and third trimesters of pregnancy. Monthly trough piperaquine samples were collected throughout pregnancy, and pre- and postdose electrocardiograms were recorded at 20, 28, and 36 weeks' gestation in each woman. The pharmacokinetics-QTc relationship for piperaquine and QTc for SP were assessed using nonlinear mixed-effects modeling. RESULTS: A positive linear relationship between piperaquine concentration and Fridericia corrected QTc interval was identified. This relationship progressively decreased from a 4.42 to 3.28 to 2.13 millisecond increase per 100 ng/mL increase in piperaquine concentration at 20, 28, and 36 weeks' gestation, respectively. Furthermore, 61% (n = 183) of women had a smaller change in QTc at week 36 than week 20. Nine women given DHA-PQ had grade 3-4 cardiac adverse events. SP was not associated with any change in QTc. CONCLUSIONS: Repeated DHA-PQ dosing did not result in increased risk of QTc prolongation and the postdose QTc intervals progressively decreased. Monthly dosing of DHA-PQ in pregnant women carries minimal risk of QTc prolongation. CLINICAL TRIALS REGISTRATION: NCT02793622.
BACKGROUND: Intermittent preventive treatment with monthly dihydroartemisinin-piperaquine (DHA-PQ) is highly effective at preventing both malaria during pregnancy and placental malaria. Piperaquine prolongs the corrected QT interval (QTc), and it is possible that repeated monthly dosing could lead to progressive QTc prolongation. Intensive characterization of the relationship between piperaquine concentration and QTc interval throughout pregnancy can inform effective, safe prevention guidelines. METHODS: Data were collected from a randomized controlled trial, where pregnant Ugandan women received malaria chemoprevention with monthly DHA-PQ (120/960 mg DHA/PQ; n = 373) or sulfadoxine-pyrimethamine (SP; 1500/75 mg; n = 375) during the second and third trimesters of pregnancy. Monthly trough piperaquine samples were collected throughout pregnancy, and pre- and postdose electrocardiograms were recorded at 20, 28, and 36 weeks' gestation in each woman. The pharmacokinetics-QTc relationship for piperaquine and QTc for SP were assessed using nonlinear mixed-effects modeling. RESULTS: A positive linear relationship between piperaquine concentration and Fridericia corrected QTc interval was identified. This relationship progressively decreased from a 4.42 to 3.28 to 2.13 millisecond increase per 100 ng/mL increase in piperaquine concentration at 20, 28, and 36 weeks' gestation, respectively. Furthermore, 61% (n = 183) of women had a smaller change in QTc at week 36 than week 20. Nine women given DHA-PQ had grade 3-4 cardiac adverse events. SP was not associated with any change in QTc. CONCLUSIONS: Repeated DHA-PQ dosing did not result in increased risk of QTc prolongation and the postdose QTc intervals progressively decreased. Monthly dosing of DHA-PQ in pregnant women carries minimal risk of QTc prolongation. CLINICAL TRIALS REGISTRATION: NCT02793622.
Authors: R Kajubi; L Huang; P Jagannathan; N Chamankhah; M Were; T Ruel; C A Koss; A Kakuru; N Mwebaza; M Kamya; D Havlir; G Dorsey; P J Rosenthal; F T Aweeka Journal: Clin Pharmacol Ther Date: 2017-05-30 Impact factor: 6.875
Authors: Abel Kakuru; Prasanna Jagannathan; Mary K Muhindo; Paul Natureeba; Patricia Awori; Miriam Nakalembe; Bishop Opira; Peter Olwoch; John Ategeka; Patience Nayebare; Tamara D Clark; Margaret E Feeney; Edwin D Charlebois; Gabrielle Rizzuto; Atis Muehlenbachs; Diane V Havlir; Moses R Kamya; Grant Dorsey Journal: N Engl J Med Date: 2016-03-10 Impact factor: 91.245
Authors: Kari R Risnes; Lars J Vatten; Jennifer L Baker; Karen Jameson; Ulla Sovio; Eero Kajantie; Merete Osler; Ruth Morley; Markus Jokela; Rebecca C Painter; Valter Sundh; Geir W Jacobsen; Johan G Eriksson; Thorkild I A Sørensen; Michael B Bracken Journal: Int J Epidemiol Date: 2011-02-15 Impact factor: 7.196
Authors: Melissa D Conrad; Daniel Mota; Marissa Foster; Stephen Tukwasibwe; Jennifer Legac; Patrick Tumwebaze; Meghan Whalen; Abel Kakuru; Patience Nayebare; Erika Wallender; Diane V Havlir; Prasanna Jagannathan; Liusheng Huang; Francesca Aweeka; Moses R Kamya; Grant Dorsey; Philip J Rosenthal Journal: J Infect Dis Date: 2017-11-15 Impact factor: 5.226
Authors: J Tarning; P Thana; A P Phyo; K M Lwin; W Hanpithakpong; E A Ashley; N P J Day; F Nosten; N J White Journal: CPT Pharmacometrics Syst Pharmacol Date: 2014-08-27